Temporal trends in the use of adjuvant systemic therapy in breast cancer - A population based study in Sweden 1976-2005

Acta Oncologica

Volumn 48, Issue 1, 2009, Pages 59-66

  Kemetli, Levent ^a   Erik Rutqvist, Lars ^b   Jonsson, Håkan ^c   Nyström, Lennarth ^c   Lenner, Per ^c   Törnberg, Sven ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c UMEÅ UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE DERIVATIVE; CYTOTOXIC AGENT; ESTROGEN RECEPTOR; GOSERELIN; MEDROXYPROGESTERONE ACETATE; MEGESTROL ACETATE; TAMOXIFEN;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; BREAST CANCER; CANCER CENTER; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER MORTALITY; CANCER SCREENING; CANCER STAGING; CONTROLLED STUDY; FEMALE; GROUPS BY AGE; HORMONAL THERAPY; HUMAN; MAJOR CLINICAL STUDY; MAMMOGRAPHY; OVARIECTOMY; PATIENT COMPLIANCE; POPULATION RESEARCH; PRACTICE GUIDELINE; PREMENOPAUSE; PRIORITY JOURNAL; PUBLIC HEALTH SERVICE; SWEDEN; TREATMENT PLANNING;

ADULT; AGE FACTORS; AGED; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEMALE; GOSERELIN; HUMANS; MEDROXYPROGESTERONE 17-ACETATE; MEGESTROL ACETATE; MIDDLE AGED; OVARIECTOMY; SWEDEN; TAMOXIFEN;

EID: 58149091518     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.1080/02841860802277471     Document Type: Article

References (24)

1. Early Breast Cancer Trialists' Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet 2005;365:1687-717.
2. Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet 1992;339:1-15.
3. Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet 1992;339:71-85.
4. Nystrom L, Rutqvist LE, Wall S, Lindgren A, Lindqvist M, Ryden S, et al. Breast cancer screening with mammography: Overview of Swedish randomised trials. Lancet 1993;341:973-8.
5. Berry DA, Cronin KA, Plevritis SK, Fryback DG, Clarke L, Zelen M, et al. Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med 2005;353:1784-92.
6. Vervoort MM, Draisma G, Fracheboud J, van de Poll-Franse LV, de Koning HJ. Trends in the usage of adjuvant systemic therapy for breast cancer in the Netherlands and its effect on mortality. Br J Cancer 2004;91:242-7.
7. Sarkeala T, Heinavaara S, Anttila A. Organised mammography screening reduces breast cancer mortality: A cohort study from Finland. Int J Cancer 2008;122:614-9.
8. Jonsson H, Tornberg S, Nystrom L, Lenner P. Service screening with mammography in Sweden-evaluation of effects of screening on breast cancer mortality in age group 40-49 years. Acta Oncol 2000;39:617-23.
9. Duffy SW, Tabar L, Chen HH, Holmqvist M, Yen MF, Abdsalah S, et al. The impact of organized mammography service screening on breast carcinoma mortality in seven Swedish counties. Cancer 2002;95:458-69.
10. Swedish Organised Service Screening Evaluation Group. Reduction in breast cancer mortality from organized service screening with mammography: 1. Further confirmation with extended data. Cancer Epidemiol Biomarkers Prev 2006;15:45-51.
11. Swedish Organised Service Screening Evaluation Group. Reduction in breast cancer mortality from the organised service screening with mammography: 2. Validation with alternative analytic methods. Cancer Epidemiol Biomarkers Prev 2006;15:52-6.
12. Tataru D, Robinson D, Moller H, Davies E. Trends in the treatment of breast cancer in Southeast England following the introduction of national guidelines. J Public Health (Oxf) 2006;28:215-7.
13. Mariotto A, Feuer EJ, Harlan LC, Wun LM, Johnson KA, Abrams J. Trends in use of adjuvant multi-agent chemotherapy and tamoxifen for breast cancer in the United States: 1975-1999. J Natl Cancer Inst 2002;94:1626-34.
14. Centre of Epidemiology. Cancer Incidence in Sweden 2006. National Board of Health and Welfare, Stockholm 2007;
15. Mattsson B, Wallgren A. Completeness of the Swedish Cancer Register. Non-notified cancer cases recorded on death certificates in 1978. Acta Radiol Oncol 1984;23:305-13.
16. Rutqvist LE, Cedermark B, Glas U, Johansson H, Nordenskjold B, Skoog L, et al. The Stockholm trial on adjuvant tamoxifen in early breast cancer. Correlation between estrogen receptor level and treatment effect. Breast Cancer Res Treat 1987;10:255-66.
17. Rutqvist LE, Cedermark B, Glas U, Johansson H, Rotstein S, Skoog L, et al. Randomized trial of adjuvant tamoxifen combined with postoperative radiation therapy or adjuvant chemotherapy in postmenopausal breast cancer. Cancer 1990;66:89-96.
18. Fisher B, Carbone P, Economou SG, Frelick R, Glass A, Lerner H, et al. 1-Phenylalanine mustard (L-PAM) in the management of primary breast cancer. A report of early findings. N Engl J Med 1975;292:117-22.
19. Bonadonna G, Brusamolino E, Valagussa P, Rossi A, Brugnatelli L, Brambilla C, et al. Combination chemotherapy as an adjuvant treatment in operable breast cancer. N Engl J Med 1976;294:405-10.
20. Baum M, Brinkley DM, Dossett JA, McPherson K, Patterson JS, Rubens RD, et al. Improved survival among patients treated with adjuvant tamoxifen after mastectomy for early breast cancer. Lancet 1983;2:450.
21. Ribeiro G, Palmer MK. Adjuvant tamoxifen for operable carcinoma of the breast: report of clinical trial by the Christie Hospital and Holt Radium Institute. Br Med J (Clin Res Ed) 1983;286:827-30.
22. NIH/NCI. Adjuvant chemotherapy for breast cancer. NIH Concensus Statement 1985;5:1-19.
23. Thuerlimann B, Koeberle D, Senn HJ. Guidelines for the adjuvant treatment of postmenopausal women with endocrine-responsive breast cancer: Past, present and future recommendations. Eur J Cancer 2007;43:46-52.
24. Swedish Organised Service Screening Evaluation Group. Effect of mammographic service screening on stage at presentation of breast cancers in Sweden. Cancer 2007;109:2205-12.